Product Code: ETC088663 | Publication Date: Jul 2023 | Updated Date: Feb 2025 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
The India radiopharmaceutical market is projected to grow at a CAGR of 8.3 % during ,owing to the increasing adoption of nuclear medicine in diagnosis and treatment, growing awareness among healthcare professionals, availability of reimbursement policies for certain radio pharmaceuticals, improvements in infrastructure and technological advancements. Additionally, rising prevalence of cancer cases and other chronic diseases across the country will also contribute towards driving the growth of this market over the forecast period.
The India radiopharmaceutical market is being driven by a number of factors, including the increasing prevalence of cancer and other chronic diseases, advancements in technology, rising healthcare expenditure, availability of funding for research and development activities, increased public awareness about the importance of early diagnosis and treatment options, and government initiatives to promote nuclear medicine. Furthermore, growing demand from emerging economies such as India along with favorable reimbursement policies are expected to provide additional boost to this market over the forecast period.
Some major challenges faced by this industry are lack of trained personnel at medical facilities using these medicines; low patient awareness levels; limited number or manufacturers dealing exclusively with radioactive drugs; inadequate storage facilities available at hospitals; etc., all combined make it difficult for manufacturers/suppliers to reach out customers who need them most urgently or timely deliveries when needed due strict regulations guiding their transportation & handling activities.
Major players operating within IndiaRadiopharmaecutical Market include GlaxoSmithKline plc., Advanced Cyclotron Systems Inc., Jubilant Pharma Ltd., IBA Molecular Imaging Sdn Bhd , Bristol-Myers Squibb Co., GE Healthcare Global Diagnostic Services LLC, Siemens Healthineers GmbH & Co KG , Eckert & Ziegler BEBIG GmbH
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 India Radiopharmaceutical Market Overview |
3.1 India Country Macro Economic Indicators |
3.2 India Radiopharmaceutical Market Revenues & Volume, 2021 & 2031F |
3.3 India Radiopharmaceutical Market - Industry Life Cycle |
3.4 India Radiopharmaceutical Market - Porter's Five Forces |
3.5 India Radiopharmaceutical Market Revenues & Volume Share, By Types, 2021 & 2031F |
3.6 India Radiopharmaceutical Market Revenues & Volume Share, By Applications, 2021 & 2031F |
3.7 India Radiopharmaceutical Market Revenues & Volume Share, By Procedural Volume Assessment, 2021 & 2031F |
3.8 India Radiopharmaceutical Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.9 India Radiopharmaceutical Market Revenues & Volume Share, By End-users, 2021 & 2031F |
4 India Radiopharmaceutical Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 India Radiopharmaceutical Market Trends |
6 India Radiopharmaceutical Market, By Types |
6.1 India Radiopharmaceutical Market, By Types |
6.1.1 Overview and Analysis |
6.1.2 India Radiopharmaceutical Market Revenues & Volume, By Types, 2018 - 2031F |
6.1.3 India Radiopharmaceutical Market Revenues & Volume, By Diagnostic Nuclear Medicine, 2018 - 2031F |
6.1.4 India Radiopharmaceutical Market Revenues & Volume, By Therapeutic Nuclear Medicine, 2018 - 2031F |
6.2 India Radiopharmaceutical Market, By Applications |
6.2.1 Overview and Analysis |
6.2.2 India Radiopharmaceutical Market Revenues & Volume, By Diagnostic Applications, 2018 - 2031F |
6.2.3 India Radiopharmaceutical Market Revenues & Volume, By Therapeutic Applications, 2018 - 2031F |
6.3 India Radiopharmaceutical Market, By Procedural Volume Assessment |
6.3.1 Overview and Analysis |
6.3.2 India Radiopharmaceutical Market Revenues & Volume, By Diagnostic Procedures, 2018 - 2031F |
6.3.3 India Radiopharmaceutical Market Revenues & Volume, By Therapeutic Procedures, 2018 - 2031F |
6.4 India Radiopharmaceutical Market, By Source |
6.4.1 Overview and Analysis |
6.4.2 India Radiopharmaceutical Market Revenues & Volume, By Nuclear Reactors, 2018 - 2031F |
6.4.3 India Radiopharmaceutical Market Revenues & Volume, By Cyclotrons, 2018 - 2031F |
6.5 India Radiopharmaceutical Market, By End-users |
6.5.1 Overview and Analysis |
6.5.2 India Radiopharmaceutical Market Revenues & Volume, By Hospitals, 2018 - 2031F |
6.5.3 India Radiopharmaceutical Market Revenues & Volume, By Ambulatory Surgical Centers, 2018 - 2031F |
6.5.4 India Radiopharmaceutical Market Revenues & Volume, By Diagnostic Centers, 2018 - 2031F |
6.5.5 India Radiopharmaceutical Market Revenues & Volume, By Cancer Research Institutes, 2018 - 2031F |
6.5.6 India Radiopharmaceutical Market Revenues & Volume, By Others, 2018 - 2031F |
7 India Radiopharmaceutical Market Import-Export Trade Statistics |
7.1 India Radiopharmaceutical Market Export to Major Countries |
7.2 India Radiopharmaceutical Market Imports from Major Countries |
8 India Radiopharmaceutical Market Key Performance Indicators |
9 India Radiopharmaceutical Market - Opportunity Assessment |
9.1 India Radiopharmaceutical Market Opportunity Assessment, By Types, 2021 & 2031F |
9.2 India Radiopharmaceutical Market Opportunity Assessment, By Applications, 2021 & 2031F |
9.3 India Radiopharmaceutical Market Opportunity Assessment, By Procedural Volume Assessment, 2021 & 2031F |
9.4 India Radiopharmaceutical Market Opportunity Assessment, By Source, 2021 & 2031F |
9.5 India Radiopharmaceutical Market Opportunity Assessment, By End-users, 2021 & 2031F |
10 India Radiopharmaceutical Market - Competitive Landscape |
10.1 India Radiopharmaceutical Market Revenue Share, By Companies, 2024 |
10.2 India Radiopharmaceutical Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |